Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically arising in the setting of chronic liver disease and cirrhosis. Major risk factors include chronic hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular pathways including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling. The combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150 trial.
Ask a research question about Hepatocellular Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Hepatocellular Carcinoma
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-09T04:09:52Z'
description: >-
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically
arising
in the setting of chronic liver disease and cirrhosis. Major risk factors include
chronic
hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated
steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular
pathways
including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling.
The
combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established
immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150
trial.
categories:
- Gastrointestinal Cancer
- Hepatobiliary Cancer
- Liver Cancer
parents:
- liver carcinoma
has_subtypes:
- name: Viral Hepatitis-Associated HCC
description: >-
HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly
oncogenic through viral integration, while HCV promotes HCC primarily through
cirrhosis
and chronic inflammation.
- name: Alcohol-Related HCC
description: >-
HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific
molecular features and generally presents at more advanced stage.
- name: MASLD-Associated HCC
description: >-
HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly
NAFLD/NASH).
Increasingly common subtype that can occur even without cirrhosis. May have distinct
immune microenvironment features affecting immunotherapy response.
- name: Fibrolamellar HCC
description: >-
Rare variant occurring in younger patients without cirrhosis. Characterized by
DNAJB1-PRKACA
fusion. Distinct clinical behavior and treatment considerations.
mappings:
ncit_mappings:
- term:
id: NCIT:C4131
label: Fibrolamellar Carcinoma
mapping_predicate: skos:closeMatch
mapping_source: NCIT
mapping_justification: NCIT provides a closely aligned fibrolamellar carcinoma term for this HCC subtype.
pathophysiology:
- name: Chronic Liver Injury and Cirrhosis
description: >-
Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent
hepatocyte death and regeneration in an inflammatory environment promotes accumulation
of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing
oxidative stress and genomic instability.
evidence:
- reference: PMID:41567639
reference_title: "Identification of novel germline and somatic mutations associated with hepatocellular carcinoma by next-generation sequencing."
supports: PARTIAL
snippet: HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases.
explanation: This abstract states that HCC commonly arises in chronic liver disease and cirrhosis, supporting the mechanism described.
cell_types:
- preferred_term: hepatocyte
term:
id: CL:0000182
label: hepatocyte
locations:
- preferred_term: liver
term:
id: UBERON:0002107
label: liver
downstream:
- target: Telomere Dysfunction and Genomic Instability
description: Repeated hepatocyte division leads to telomere shortening
- target: Accumulation of Driver Mutations
description: Chronic regeneration promotes mutation accumulation
- name: Telomere Dysfunction and Genomic Instability
description: >-
Chronic hepatocyte proliferation leads to telomere shortening, causing genomic
instability.
TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase
to enable unlimited replication. This creates a checkpoint bypass allowing survival
of genetically unstable cells.
biological_processes:
- preferred_term: telomere maintenance
modifier: ABNORMAL
term:
id: GO:0000723
label: telomere maintenance
downstream:
- target: WNT/Beta-Catenin Pathway Activation
description: Genomic instability promotes acquisition of pathway-activating mutations
- name: Accumulation of Driver Mutations
description: >-
Multiple driver genes are recurrently mutated in HCC, including TERT promoter
(60%),
TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect
telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.
biological_processes:
- preferred_term: DNA repair
modifier: DECREASED
term:
id: GO:0006281
label: DNA repair
downstream:
- target: PI3K/AKT/mTOR Pathway Activation
description: Somatic and expression-level pathway changes select for oncogenic growth signaling.
- name: WNT/Beta-Catenin Pathway Activation
description: >-
Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1
lead to constitutive WNT pathway activation. This drives cell proliferation and
is
associated with a distinct molecular subclass of HCC with specific clinical features
including cholestasis and immune exclusion.
biological_processes:
- preferred_term: Wnt signaling pathway
modifier: INCREASED
term:
id: GO:0016055
label: Wnt signaling pathway
downstream:
- target: Enhanced Hepatocyte Proliferation
description: WNT signaling drives cell proliferation and stemness
- name: PI3K/AKT/mTOR Pathway Activation
description: >-
PI3K/AKT/mTOR signaling is a recurrent oncogenic axis in HCC. PI3K/Akt
activation is reported in 40-60% of HCC tissue, and dysregulated
pathway-associated genes and upstream receptor inputs increase AKT/TOR
signaling, supporting hepatocyte survival, anabolic growth, proliferation, and
immune infiltration patterns relevant to targeted therapy and immunotherapy
response.
biological_processes:
- preferred_term: TOR signaling
modifier: INCREASED
term:
id: GO:0031929
label: TOR signaling
- preferred_term: phosphatidylinositol-mediated signaling
modifier: INCREASED
term:
id: GO:0048015
label: phosphatidylinositol-mediated signaling
evidence:
- reference: PMID:29984212
reference_title: Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The signaling pathways known to be activated in HCC tissue include the Wnt/β-catenin pathway (up to 50% of HCC), the phosphatidylinositol-3-kinase and protein kinase B (PI3K/Akt) pathway (40–60% of HCC), the Myc pathway (30–60%), the Hedgehog pathway (50–60%), and the MET pathway (30–40%).
explanation: This review summarizes human HCC tissue data and supports recurrent PI3K/Akt activation in a large fraction of HCC.
- reference: PMID:35592706
reference_title: "PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: The dysregulated PI3K/AKT/mTOR pathway acts as the main regulator of tumorigenesis in hepatocellular carcinoma (HCC).
explanation: >-
This bioinformatic HCC cohort analysis directly supports PI3K/AKT/mTOR
dysregulation as an oncogenic signaling axis and links pathway-associated
gene signatures to immune infiltration.
downstream:
- target: Enhanced Hepatocyte Proliferation
description: PI3K/AKT/mTOR activation promotes tumor-cell growth and survival signaling.
- target: Immune Evasion and Immunosuppressive Microenvironment
description: Pathway-associated signatures correlate with immune infiltration and checkpoint expression.
- name: TP53 Pathway Inactivation
description: >-
TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated
tumors. Loss of p53 function removes a critical checkpoint, allowing survival
of cells
with DNA damage and promoting genomic instability.
biological_processes:
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
- name: Enhanced Hepatocyte Proliferation
description: >-
Combined effects of telomerase reactivation, cell cycle checkpoint loss, and
mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
- name: Angiogenesis and VEGF Signaling
description: >-
HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes
new blood vessel formation supplying the tumor. VEGF also has immunosuppressive
effects, contributing to the immune-excluded microenvironment. This provides the
rationale for anti-VEGF therapy in combination with immunotherapy.
evidence:
- reference: PMID:19637355
reference_title: "Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature."
supports: SUPPORT
snippet: "Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to play a considerable role in its development and progression."
explanation: "Abstract notes HCC is highly vascular and angiogenesis plays a major role, supporting this mechanism."
biological_processes:
- preferred_term: angiogenesis
modifier: INCREASED
term:
id: GO:0001525
label: angiogenesis
downstream:
- target: Immune Evasion and Immunosuppressive Microenvironment
description: VEGF-mediated immunosuppression contributes to T cell exclusion and checkpoint upregulation
- name: Immune Evasion and Immunosuppressive Microenvironment
conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
description: >-
HCC develops in a chronically inflamed liver with an inherently
immunosuppressive microenvironment. Tumor cells upregulate PD-L1,
VEGF-mediated immunosuppression excludes effector T cells, and
recruitment of regulatory T cells, myeloid-derived suppressor cells,
and tumor-associated macrophages creates an immune-tolerant niche.
The combination of anti-PD-L1 with anti-VEGF addresses both the
checkpoint-mediated and VEGF-mediated immunosuppression.
cell_types:
- preferred_term: CD8-positive, alpha-beta T cell
term:
id: CL:0000625
label: CD8-positive, alpha-beta T cell
biological_processes:
- preferred_term: Negative Regulation of T Cell Mediated Immunity
term:
id: GO:0002710
label: negative regulation of T cell mediated immunity
modifier: INCREASED
evidence:
- reference: PMID:32158599
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The HCC tumor microenvironment is characterized by a dysfunction of
the immune system through multiple mechanisms, including accumulation
of various immunosuppressive factors, recruitment of regulatory T cells
and myeloid-derived suppressor cells, and induction of T cell exhaustion
accompanied with the interaction between immune checkpoint ligands and
receptors.
explanation: >-
Review specifically describes HCC's immunosuppressive microenvironment
including Treg and MDSC recruitment, T cell exhaustion, and checkpoint
ligand-receptor interactions — directly supporting all claims in this
node about HCC immune evasion mechanisms.
histopathology:
- name: Hepatocellular Carcinoma
finding_term:
preferred_term: Hepatocellular Carcinoma
term:
id: NCIT:C3099
label: Hepatocellular Carcinoma
frequency: VERY_FREQUENT
description: Hepatocellular carcinoma is the most common primary liver malignancy.
evidence:
- reference: PMID:27785449
reference_title: "Hepatocellular carcinoma: a review."
supports: SUPPORT
snippet: "Hepatocellular carcinoma (HCC) is the most common primary liver malignancy"
explanation: Abstract states that HCC is the most common primary liver malignancy.
phenotypes:
- category: Hepatic
name: Hepatomegaly
frequency: FREQUENT
description: >-
Liver enlargement from tumor mass. May be palpable as a hard, irregular mass in
the
right upper quadrant.
phenotype_term:
preferred_term: Hepatomegaly
term:
id: HP:0002240
label: Hepatomegaly
- category: Hepatic
name: Ascites
frequency: FREQUENT
description: >-
Abdominal fluid accumulation from portal hypertension (cirrhosis) and/or tumor-related
factors. Presence indicates advanced disease and decompensated liver function.
phenotype_term:
preferred_term: Ascites
term:
id: HP:0001541
label: Ascites
- category: Hepatic
name: Jaundice
frequency: OCCASIONAL
description: >-
Yellowing of skin and sclera from elevated bilirubin. May result from biliary
obstruction
by tumor, hepatic failure, or diffuse tumor infiltration.
phenotype_term:
preferred_term: Jaundice
term:
id: HP:0000952
label: Jaundice
- category: Gastrointestinal
name: Abdominal Pain
frequency: FREQUENT
description: >-
Right upper quadrant pain or discomfort from liver capsule distension or tumor
growth.
Sudden severe pain may indicate tumor rupture.
phenotype_term:
preferred_term: Abdominal pain
term:
id: HP:0002027
label: Abdominal pain
- category: Constitutional
name: Weight Loss
frequency: VERY_FREQUENT
description: >-
Unintentional weight loss is common in HCC due to cancer cachexia, reduced oral
intake,
and altered metabolism.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Constitutional
name: Fatigue
frequency: VERY_FREQUENT
description: >-
Fatigue from liver dysfunction, anemia, and cancer-related factors.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Gastrointestinal
name: Nausea
frequency: FREQUENT
description: >-
Nausea and anorexia from liver dysfunction and advanced disease.
phenotype_term:
preferred_term: Nausea
term:
id: HP:0002018
label: Nausea
biochemical:
- name: Alpha-Fetoprotein (AFP)
notes: >-
Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400
ng/mL
are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with
imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.
- name: Liver Function Tests
notes: >-
Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern
depends
on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic
reserve
and guides treatment decisions.
- name: PIVKA-II (DCP)
notes: >-
Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated
when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.
diagnosis:
- name: Ultrasound and AFP Surveillance
description: >-
High-risk patients, especially those with cirrhosis or chronic HBV, are
surveilled with repeated liver ultrasonography plus serum alpha-fetoprotein
to detect HCC at an earlier, potentially curable stage.
diagnosis_term:
preferred_term: ultrasonography procedure
term:
id: MAXO:0000072
label: ultrasonography procedure
markers: Alpha-fetoprotein (AFP)
results: Detection of a suspicious liver lesion or rising AFP prompts diagnostic cross-sectional imaging.
evidence:
- reference: DOI:10.3350/cmh.2024.0824
reference_title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV).
explanation: This review summarizes current surveillance practice using liver ultrasound plus AFP in high-risk patients.
- name: Multiphasic CT/MRI or Contrast-Enhanced Ultrasound Imaging Diagnosis
description: >-
In high-risk patients, HCC can be diagnosed noninvasively using guideline
imaging algorithms such as LI-RADS/EASL that combine arterial phase
hyperenhancement, washout, capsule, size, and growth features on
contrast-enhanced CT, MRI, or ultrasound.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
results: LI-RADS or comparable guideline category consistent with definitive HCC.
evidence:
- reference: DOI:10.1007/s00330-024-10606-w
reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: These allow the diagnosis of HCC in high-risk patients in the presence of typical imaging features on contrast-enhanced CT, MRI, or contrast-enhanced ultrasound.
explanation: ESR/ESGAR practice recommendations summarize the noninvasive imaging context for HCC diagnosis.
- reference: DOI:10.1007/s00330-024-10606-w
reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Size, non-rim arterial phase hyperenhancement, non-peripheral washout, enhancing capsule, and growth are major imaging features and they should be combined for the diagnosis of HCC.
explanation: This supports the specific imaging features used in LI-RADS/EASL-style diagnostic algorithms.
- name: BCLC Staging Assessment
description: >-
Barcelona Clinic Liver Cancer staging integrates tumor burden, liver function,
and performance status to classify HCC stage and guide treatment selection.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
results: BCLC stage assignment used for prognosis and treatment planning.
evidence:
- reference: DOI:10.1007/s12029-023-00961-0
reference_title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Fourteen guidelines (67%) endorsed using the BCLC staging system.
explanation: This systematic review of guidelines supports BCLC staging as a commonly endorsed HCC staging framework.
genetic:
- name: TERT Promoter
association: Somatic Activating Mutation
notes: >-
TERT promoter mutations (C228T, C250T) are the most common genetic alterations
in HCC,
present in approximately 60% of cases. These mutations create binding sites for
ETS
transcription factors, reactivating telomerase expression and enabling unlimited
cell division.
- name: TP53
association: Somatic Loss of Function
notes: >-
TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and
aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated
with aflatoxin B1 exposure.
- name: CTNNB1
association: Somatic Activating Mutation
notes: >-
CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive
WNT pathway activation. Associated with distinct clinical features including
cholestasis and immune exclusion, potentially affecting immunotherapy response.
- name: AXIN1
association: Somatic Loss of Function
notes: >-
AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating
WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.
- name: ARID1A
association: Somatic Loss of Function
notes: >-
ARID1A mutations affect chromatin remodeling and occur in approximately 10% of
HCC.
Part of the SWI/SNF complex alterations seen across multiple cancer types.
treatments:
- name: Atezolizumab plus Bevacizumab
description: >-
First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1
(atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall
survival compared to sorafenib. Requires adequate liver function (Child-Pugh A)
and no high-risk varices. Immunotherapy trials in HCC require careful interpretation due to
delayed treatment effects and potential violations of proportional hazard assumptions,
which may affect the apparent magnitude of benefit from surrogate endpoints like PFS.
notes: >-
HCC trial interpretation requires careful consideration of endpoint selection and
validity of surrogates. Overall survival remains the most robust endpoint, though
progression-free survival, time-to-progression, and objective response rate are
frequently used to accelerate drug development. The validity of surrogate endpoints
in HCC is debated due to tumor heterogeneity, competing risks related to liver disease
(e.g., hepatic decompensation, hepatic encephalopathy), and the influence of
post-progression therapies. Immunotherapy trials like IMbrave150 present additional
challenges: delayed treatment effects that violate traditional proportional hazards
assumptions and complex patterns of response not fully captured by conventional
endpoint definitions. These methodological nuances should be considered when
interpreting efficacy data and comparing trials with different endpoints and
follow-up durations.
evidence:
- reference: PMID:39687036
reference_title: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"
explanation: "IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib."
- reference: PMID:42184925
reference_title: "Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma."
supports: PARTIAL
evidence_source: OTHER
snippet: "immunotherapy has introduced challenges to traditional statistical models through delayed treatment effects and violations of the proportional hazard assumption"
explanation: >-
This methodology review highlights critical interpretation issues for immunotherapy trials in HCC, including delayed treatment effects and proportional hazards violations that affect OS and PFS endpoint validity in IMbrave150 and similar trials.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: atezolizumab
term:
id: NCIT:C106250
label: Atezolizumab
- preferred_term: bevacizumab
term:
id: NCIT:C2039
label: Bevacizumab
target_mechanisms:
- target: Immune Evasion and Immunosuppressive Microenvironment
treatment_effect: INHIBITS
description: >-
Atezolizumab (anti-PD-L1) blocks PD-L1-mediated T cell suppression
while bevacizumab (anti-VEGF) reverses VEGF-mediated immunosuppression,
together restoring anti-tumor immunity in HCC.
evidence:
- reference: PMID:39687036
reference_title: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"
explanation: >-
Superior outcomes with combined anti-PD-L1/anti-VEGF demonstrate that
targeting both checkpoint-mediated and VEGF-mediated immunosuppression
is effective in HCC.
- target: Angiogenesis and VEGF Signaling
treatment_effect: INHIBITS
description: >-
Bevacizumab directly inhibits VEGF-driven angiogenesis that sustains
HCC tumor growth.
evidence:
- reference: PMID:32402160
reference_title: "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
atezolizumab combined with bevacizumab resulted in better overall and
progression-free survival outcomes than sorafenib.
explanation: >-
The IMbrave150 trial established the anti-VEGF antibody bevacizumab
(combined with atezolizumab) as effective first-line therapy, supporting
its action on the angiogenesis/VEGF-signaling node in HCC.
- name: Durvalumab plus Tremelimumab
description: >-
Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab
(anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival
compared to sorafenib. Option for patients who cannot receive bevacizumab. Like other
HCC immunotherapy trials, trial interpretation requires careful consideration of delayed treatment
effects and proportional hazards violations when assessing surrogate endpoints.
evidence:
- reference: PMID:38382875
reference_title: "Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS."
explanation: >-
The phase III HIMALAYA trial provides primary efficacy evidence that the STRIDE regimen (durvalumab plus a single priming dose of tremelimumab) significantly improved overall survival versus sorafenib, directly anchoring the efficacy claim in the treatment description.
- reference: PMID:42184925
reference_title: "Beyond hazard ratios: interpreting trial endpoints and survival analysis in systemic therapy for hepatocellular carcinoma."
supports: PARTIAL
evidence_source: OTHER
snippet: "The validity of surrogate endpoints in hepatocellular carcinoma remains debated due to tumor heterogeneity, competing risks related to liver disease, and the influence of post‑progression therapies"
explanation: >-
This methodology review clarifies critical context for HIMALAYA trial interpretation: surrogate endpoints (PFS, TTP, ORR) in HCC are complicated by tumor heterogeneity, competing risks from underlying cirrhosis, and post-progression therapy confounding, highlighting why OS improvement is particularly meaningful for durvalumab + tremelimumab.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: durvalumab
term:
id: NCIT:C103194
label: Durvalumab
- preferred_term: tremelimumab
term:
id: NCIT:C49085
label: Tremelimumab
target_mechanisms:
- target: Immune Evasion and Immunosuppressive Microenvironment
treatment_effect: INHIBITS
description: >-
Durvalumab (anti-PD-L1) blocks adaptive immune resistance while
tremelimumab (anti-CTLA-4) priming dose expands the T cell repertoire,
together overcoming the immunosuppressive HCC microenvironment.
evidence:
- reference: PMID:38382875
reference_title: "Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly
improved overall survival (OS) versus sorafenib; durvalumab monotherapy
was noninferior to sorafenib for OS.
explanation: >-
The phase III HIMALAYA study shows dual anti-CTLA-4/anti-PD-L1 blockade
(STRIDE) improves survival, supporting its action on the immune-evasion
and immunosuppressive-microenvironment node in HCC.
- name: Sorafenib
description: >-
Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy
to improve survival in HCC. Now used in second line or when immunotherapy is
contraindicated.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: sorafenib
term:
id: CHEBI:50924
label: sorafenib
- name: Lenvatinib
description: >-
Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT.
Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: lenvatinib
term:
id: CHEBI:85994
label: lenvatinib
- name: Surgical Resection
description: >-
Potentially curative for early-stage HCC in patients with preserved liver function
(Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate
future liver remnant.
treatment_term:
preferred_term: hepatic resection
term:
id: NCIT:C15249
label: Hepatectomy
- name: Liver Transplantation
description: >-
Potentially curative treatment that addresses both tumor and underlying cirrhosis.
Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less,
no
vascular invasion, no metastases) guide patient selection. Limited by organ availability.
treatment_term:
preferred_term: organ transplantation
term:
id: MAXO:0010039
label: organ transplantation
- name: Transarterial Chemoembolization (TACE)
description: >-
Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery
followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be
used
as bridge to transplant or with systemic therapy.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
- name: Radiofrequency/Microwave Ablation
description: >-
Thermal ablation for small tumors (typically less than 3 cm). Effective alternative
to resection for early-stage HCC, particularly in patients with limited liver
function.
treatment_term:
preferred_term: ablation therapy
term:
id: MAXO:0000452
label: ablation therapy
disease_term:
preferred_term: hepatocellular carcinoma
term:
id: MONDO:0007256
label: hepatocellular carcinoma
mappings:
mondo_mappings:
- term:
id: MONDO:0007256
label: hepatocellular carcinoma
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: MONDO provides an exact disease term for hepatocellular carcinoma.
icd10cm_mappings:
- term:
id: ICD10CM:C22.0
label: Liver cell carcinoma
mapping_predicate: skos:exactMatch
mapping_source: ICD-10-CM
mapping_justification: ICD-10-CM provides an exact code for liver cell carcinoma / hepatocellular carcinoma.
ncit_mappings:
- term:
id: NCIT:C3099
label: Hepatocellular Carcinoma
mapping_predicate: skos:exactMatch
mapping_source: NCIT
mapping_justification: NCIT provides an exact neoplasm term for hepatocellular carcinoma.
classifications:
icdo_morphology:
classification_value: Carcinoma
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
evidence:
- reference: DOI:10.1007/s00330-024-10606-w
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."
explanation: ESR/ESGAR practice recommendations characterise HCC as a primary hepatic malignancy and a leading cancer cause of death, anchoring the Harrison's Oncology and Hematology classification.
- classification_value: GASTROINTESTINAL
evidence:
- reference: DOI:10.1007/s00330-024-10606-w
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide."
explanation: The same review locates HCC in the liver, supporting an additional Harrison's Gastrointestinal classification since hepatic cancers are addressed in the GI Part.
references:
- reference: DOI:10.1007/s00330-024-10606-w
title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
supporting_text: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
evidence:
- reference: DOI:10.1007/s00330-024-10606-w
reference_title: 'ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and a leading cause of cancer related death worldwide.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1007/s12029-023-00961-0
title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
supporting_text: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
evidence:
- reference: DOI:10.1007/s12029-023-00961-0
reference_title: 'Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review'
supports: SUPPORT
evidence_source: OTHER
snippet: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1159/000539371
title: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
supporting_text: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.
evidence:
- reference: DOI:10.1159/000539371
reference_title: EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
supports: SUPPORT
evidence_source: OTHER
snippet: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12885-023-11112-w
title: 'Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
supporting_text: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
evidence:
- reference: DOI:10.1186/s12885-023-11112-w
reference_title: 'Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis'
supports: SUPPORT
evidence_source: OTHER
snippet: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC).
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12885-024-12407-2
title: Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
supporting_text: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
evidence:
- reference: DOI:10.1186/s12885-024-12407-2
reference_title: Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma (HCC) genomic research has discovered actionable genetic changes that might guide treatment decisions and clinical trials.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1186/s12920-024-01965-w
title: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
supporting_text: Genomic landscape of hepatocellular carcinoma in Egyptian patients by whole exome sequencing
- reference: DOI:10.1186/s12943-024-02062-3
title: 'Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
supporting_text: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
evidence:
- reference: DOI:10.1186/s12943-024-02062-3
reference_title: 'Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts'
supports: SUPPORT
evidence_source: OTHER
snippet: Tumor heterogeneity presents a formidable challenge in understanding the mechanisms driving tumor progression and metastasis.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.1200/jco.23.02745
title: 'Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
supporting_text: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
evidence:
- reference: DOI:10.1200/jco.23.02745
reference_title: 'Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update'
supports: SUPPORT
evidence_source: OTHER
snippet: To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.14744/hf.2023.2023.0028
title: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
supporting_text: Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
- reference: DOI:10.20517/2394-5079.2024.16
title: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
supporting_text: Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
- reference: DOI:10.21037/hbsn-22-469
title: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
supporting_text: 'A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights'
- reference: DOI:10.2147/jhc.s478604
title: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
supporting_text: 'Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study'
- reference: DOI:10.3350/cmh.2024.0824
title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
supporting_text: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
evidence:
- reference: DOI:10.3350/cmh.2024.0824
reference_title: 'Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3389/fphar.2024.1416295
title: Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
supporting_text: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
evidence:
- reference: DOI:10.3389/fphar.2024.1416295
reference_title: Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/biom14060656
title: Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
supporting_text: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
evidence:
- reference: DOI:10.3390/biom14060656
reference_title: Molecular Mechanisms in Tumorigenesis of Hepatocellular Carcinoma and in Target Treatments—An Overview
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma is the most common primary malignancy of the liver, with hepatocellular differentiation.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/biomedicines12071624
title: 'Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
supporting_text: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
evidence:
- reference: DOI:10.3390/biomedicines12071624
reference_title: 'Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges'
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16030666
title: 'Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
supporting_text: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
evidence:
- reference: DOI:10.3390/cancers16030666
reference_title: 'Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16050901
title: 'Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
supporting_text: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
evidence:
- reference: DOI:10.3390/cancers16050901
reference_title: 'Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3390/cancers16233933
title: 'Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
supporting_text: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
evidence:
- reference: DOI:10.3390/cancers16233933
reference_title: 'Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.3748/wjg.v30.i19.2488
title: Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
supporting_text: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
evidence:
- reference: DOI:10.3748/wjg.v30.i19.2488
reference_title: Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.4254/wjh.v16.i5.716
title: 'Genetic screening of liver cancer: State of the art'
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
supporting_text: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
evidence:
- reference: DOI:10.4254/wjh.v16.i5.716
reference_title: 'Genetic screening of liver cancer: State of the art'
supports: SUPPORT
evidence_source: OTHER
snippet: Liver cancer, primarily hepatocellular carcinoma, remains a global health challenge with rising incidence and limited therapeutic options.
explanation: Deep research cited this publication as relevant literature for Hepatocellular Carcinoma.
- reference: DOI:10.7150/thno.95971
title: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings:
- statement: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
supporting_text: Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma
- reference: DOI:10.1159/000539897
title: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
found_in:
- Hepatocellular_Carcinoma-deep-research-falcon.md
findings: []
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Hepatocellular Carcinoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Hepatocellular carcinoma is the most common primary hepatic malignancy and a leading cause of cancer mortality worldwide (cannella2024esressentialsdiagnosis pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 1-3). HCC typically arises in the setting of chronic liver disease/cirrhosis; cirrhosis confers markedly elevated risk compared with non-cirrhotic liver, and clinical management must simultaneously address the tumor and the underlying liver dysfunction (hwang2024hepatocellularcarcinomaupdates pages 1-3, mattos2024hepatocellularcarcinomatherole pages 1-2).
A compact normalization table is provided below.
| Disease name | Common synonyms / alternative names | Identifier system | Code / ID | Status / note | Source | URL / DOI |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | HCC; hepatoma | Open Targets / EFO | EFO_0000182 | Retrieved in current evidence as the disease entity used for target associations | Open Targets disease-target association (OpenTargets Search: hepatocellular carcinoma) | https://platform.opentargets.org/disease/EFO_0000182 |
| Hepatocellular carcinoma | HCC; hepatoma | ICD-10 | C22.0 | Malignant neoplasm of liver and intrahepatic bile ducts, liver cell carcinoma | AASLD/CMH surveillance and diagnosis reviews referencing current HCC guideline nomenclature and disease classification context (hwang2024hepatocellularcarcinomaupdates pages 6-7, hwang2024hepatocellularcarcinomaupdates pages 1-3) | https://icd.who.int/browse10/2019/en#/C22.0 |
| Hepatocellular carcinoma | HCC; hepatoma | MONDO | Not available | MONDO identifier was not retrieved in the current evidence set and should be treated as unavailable here | No MONDO ID recovered in gathered evidence; Open Targets search returned EFO disease mapping instead (OpenTargets Search: hepatocellular carcinoma) | Not available |
| Hepatocellular carcinoma | HCC; hepatoma | MeSH | Not retrieved in current evidence | MeSH identifier not directly retrieved in the available evidence, though HCC is consistently defined as the major primary liver cancer | Recent HCC reviews/guidelines use the disease term consistently but do not provide a MeSH code in the retrieved excerpts (hwang2024hepatocellularcarcinomaupdates pages 1-3, cannella2024esressentialsdiagnosis pages 1-3) | https://www.ncbi.nlm.nih.gov/mesh/ |
| Hepatocellular carcinoma | HCC; hepatoma; liver cell carcinoma | Guideline/common usage | Not a formal code | Common naming supported by recent guideline and review literature; HCC is described as the predominant primary liver cancer | Hwang et al. 2024; ESR/ESGAR 2024; ASCO 2024 (hwang2024hepatocellularcarcinomaupdates pages 1-3, cannella2024esressentialsdiagnosis pages 1-3, gordan2024systemictherapyfor pages 1-2) | https://doi.org/10.3350/cmh.2024.0824 ; https://doi.org/10.1007/s00330-024-10606-w ; https://doi.org/10.1200/JCO.23.02745 |
Table: This table compiles the key identifiers and common names for hepatocellular carcinoma that were recoverable from the gathered evidence. It is useful as a compact normalization reference for knowledge-base curation, while clearly marking identifiers that were not retrieved in the current evidence set.
Synonyms / alternative names: “HCC”, “hepatoma”, “liver cell carcinoma” (common clinical usage in contemporary guidelines/reviews) (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 1-3).
The information synthesized here is largely aggregated disease-level evidence from international guidelines/reviews and meta-analyses (e.g., ASCO 2024 systemic therapy guideline update; ESR/ESGAR 2024 imaging recommendations; EASL-EASD-EASO 2024 MASLD guideline; CMH 2024 epidemiology review) plus selected primary/real-world clinical studies and genomic cohort studies (gordan2024systemictherapyfor pages 1-2, cannella2024esressentialsdiagnosis pages 1-3, (easo)2024easleasdeasoclinicalpractice pages 46-48, hwang2024hepatocellularcarcinomaupdates pages 1-3, shen2024efficacyofatezolizumab pages 1-2, song2024genomicprofilinginforms pages 1-2).
HCC arises through the interaction of chronic liver injury/inflammation/fibrosis with acquired (somatic) genetic and epigenetic alterations in hepatocytes, commonly driven by: chronic viral hepatitis (HBV/HCV), alcohol-associated liver disease (ALD), and metabolic dysfunction–associated steatotic liver disease (MASLD) / metabolic dysfunction–associated steatohepatitis (MASH) (hwang2024hepatocellularcarcinomaupdates pages 1-3, kinsey2024managementofhepatocellular pages 1-2).
Major clinical risk factors consistently highlighted across guidelines include cirrhosis, chronic HBV infection, chronic HCV infection, alcohol use/ALD, obesity, type 2 diabetes, and MASLD/MASH; aflatoxin exposure remains important in some regions (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 4-6).
Regional/global etiology proportions (GBD 2021, liver cancer overall): HBV ~39% of cases (37% of deaths), HCV ~29% (30% deaths), ALD ~19% (19% deaths) (hwang2024hepatocellularcarcinomaupdates pages 4-6).
Genetic susceptibility / modifiers (selected examples): A 2024 “state of the art” genetic screening review notes that germline polymorphisms in lipid metabolism genes (e.g., PNPLA3, TM6SF2, HSD17B13) modulate NASH/alcohol-related disease severity and influence HCC risk, and that variants in WNT genes or TERT can modulate HCC risk (peruhova2024geneticscreeningof pages 2-4).
At the population level, the declining fraction of HBV- and HCV-related HCC is attributed to HBV vaccination and effective antiviral therapy reducing chronic viral hepatitis burden (hwang2024hepatocellularcarcinomaupdates pages 1-3, hwang2024hepatocellularcarcinomaupdates pages 4-6). In MASLD, reduction/regression of fibrosis is linked with reduced liver-related risk, supporting fibrosis reduction as a protective strategy against downstream outcomes including HCC ((easo)2024easleasdeasoclinicalpractice pages 46-48).
The etiology-specific differences in key somatic events (e.g., TERT promoter mutation rates differing by HBV/HCV/nonviral) highlight gene–environment interplay (virus-driven vs metabolic drivers with different mutational selection pressures) (ucdal2024crosstalkbetween pages 1-2).
HCC is frequently asymptomatic until advanced stages; consequently, surveillance aims to detect tumors at a curable stage (wu2024hepatocellularcarcinomasurveillance pages 1-2). Underlying cirrhosis drives common co-phenotypes/complications that influence treatment eligibility (portal hypertension/varices, synthetic dysfunction, etc.), motivating staging systems that integrate liver function and performance status (seth2024clinicalpracticeguidelines pages 2-3, gordan2024systemictherapyfor pages 1-2).
Because detailed symptom-frequency tables were not available in the retrieved evidence excerpts, below are suggested HPO terms for common HCC/cirrhosis-associated clinical features seen in practice (term suggestions only; frequencies not extracted here): - HP:0001402 Hepatomegaly - HP:0001394 Jaundice - HP:0001548 Ascites - HP:0002615 Esophageal varices - HP:0003073 Elevated serum alpha-fetoprotein - HP:0002240 Abdominal pain
A multidisciplinary, patient-centered model and early palliative-care integration are increasingly emphasized in 2024-era HCC management reviews because liver dysfunction plus cancer symptoms/toxicities can substantially impair daily functioning (kinsey2024managementofhepatocellular pages 1-2).
HCC is dominated by somatic alterations rather than single-gene Mendelian causation. Commonly altered genes repeatedly highlighted include TERT promoter, TP53, and Wnt/β-catenin pathway genes (e.g., CTNNB1, AXIN1) along with chromatin regulators (ARID1A/ARID2), and signaling pathway members spanning PI3K/AKT/mTOR, RAS/MAPK, Hippo, Notch, etc. (ucdal2024crosstalkbetween pages 1-2, szilveszter2024molecularmechanismsin pages 2-4, peruhova2024geneticscreeningof pages 2-4).
Quantitative frequency ranges (from a 2024 clinical-genomics cohort summary): TERT promoter ~60%; TP53 ~12–48%; CTNNB1 ~11–37% (song2024genomicprofilinginforms pages 1-2). Another 2024 mechanistic review describes TERT promoter as “the single most common HCC mutation (up to 60%)” and provides etiology-stratified frequencies: HCV ~44%, non-viral ~38%, HBV ~23% (ucdal2024crosstalkbetween pages 1-2).
A common causal chain described in contemporary reviews is: 1) chronic injury (HBV/HCV, alcohol, MASLD/MASH) → 2) inflammation/fibrosis/cirrhosis microenvironment → 3) selection for telomerase activation (TERT promoter) and oncogenic signaling alterations (Wnt/β-catenin, PI3K/AKT/mTOR, RAS/MAPK, Hippo, Notch) → 4) tumor initiation/progression with immunosuppressive tumor microenvironment and angiogenesis → 5) clinical HCC with recurrence/metastasis risk (hwang2024hepatocellularcarcinomaupdates pages 1-3, szilveszter2024molecularmechanismsin pages 2-4, pessino2024hepatocellularcarcinomaold pages 15-17).
While detailed locus-level methylation/histone data were not extracted from a single primary epigenome paper in this run, 2024 reviews emphasize that harmful epigenetic modifications (DNA methylation/chromatin changes) interact with driver mutations and contribute to intratumoral heterogeneity and progression; these are also being explored therapeutically in combination regimens (szilveszter2024molecularmechanismsin pages 2-4).
HBV and HCV are key infectious causes (hwang2024hepatocellularcarcinomaupdates pages 4-6). Chronic HBV/HCV contributions to liver cancer incidence and death are quantified above (hwang2024hepatocellularcarcinomaupdates pages 4-6).
Pathways repeatedly emphasized in 2024-era mechanistic and clinical-genomics literature include: - Wnt/β-catenin (CTNNB1, AXIN1) (ucdal2024crosstalkbetween pages 1-2, szilveszter2024molecularmechanismsin pages 2-4) - PI3K/AKT/mTOR (common pathway alteration; mutational contributors include PTEN, PIK3CA, MTOR, AKT2) (pessino2024hepatocellularcarcinomaold pages 15-17) - RAS/RAF/MAPK (frequently altered signaling; also prominent in DEN mouse model mutational spectrum) (szilveszter2024molecularmechanismsin pages 2-4, cigliano2024preclinicalmodelsof pages 9-10) - Hippo, Notch, Hedgehog (enriched in WES pathway analyses and reviews) (kassem2024genomiclandscapeof pages 1-2, szilveszter2024molecularmechanismsin pages 2-4)
Single-cell and spatial transcriptomics studies in 2024 provide mechanistic insight into why only a subset of patients respond to PD-1/PD-L1 blockade: - An “immune barrier” composed of macrophages and cancer-associated fibroblasts (CAFs) can physically/chemically impede CD8+ T-cell infiltration; non-responders show increased immunosuppressive macrophage states (e.g., TREM2+ macrophages, SPP1+ macrophages) and CAF markers (e.g., POSTN) (li2024singlecellanalyses pages 1-2, li2024singlecellanalyses pages 6-8). - A large integrated single-cell+spatial analysis mapped malignant-cell heterogeneity and identified a pro-metastatic EMT-like tumor-cell subtype with TGF-β/SMAD3 activation, associated with worse prognosis and an immune-poor (“deserted”) microenvironment; a tumor–fibroblast feedback loop (SPP1–CD44 and CCN2/TGF-β–TGFBR1) was proposed as actionable (guo2024singlecelltumorheterogeneity pages 1-2).
Given the strong emphasis on transcriptional reprogramming, signaling, and metabolism in HCC, commonly implicated compartments include nucleus (GO:0005634), mitochondrion (GO:0005739), and plasma membrane (GO:0005886) (pathway-level support in 2024 mechanistic reviews) (szilveszter2024molecularmechanismsin pages 2-4).
HCC usually develops over years in the context of chronic liver disease with progressive fibrosis/cirrhosis. Contemporary reviews emphasize that shifting etiologies (MASLD/ALD) may worsen ultrasound performance and complicate surveillance because MASLD-associated HCC can occur without cirrhosis (25–30% of MASLD-HCC cases without cirrhosis) (hwang2024hepatocellularcarcinomaupdates pages 6-7).
Major guidelines commonly endorse Barcelona Clinic Liver Cancer (BCLC) staging to integrate tumor burden, liver function, and performance status, guiding therapy selection (seth2024clinicalpracticeguidelines pages 2-3, seth2024clinicalpracticeguidelines pages 10-11).
Sex disparity (higher incidence and mortality in men) and marked geographic variation by etiology (HBV-dominant regions in Asia/Africa; HCV prominent in specific countries; rising MASLD/ALD in Western settings) are emphasized in 2024 reviews (kinsey2024managementofhepatocellular pages 1-2, hwang2024hepatocellularcarcinomaupdates pages 1-3).
AASLD-aligned surveillance: semi-annual (every 6 months) abdominal ultrasound plus AFP for at-risk populations (e.g., Child-Pugh A/B cirrhosis any etiology; Child-Pugh C if transplant candidate; selected non-cirrhotic HBV by risk stratification) (wu2024hepatocellularcarcinomasurveillance pages 4-5, hwang2024hepatocellularcarcinomaupdates pages 6-7). A contemporary review underscores that even ultrasound+AFP still misses over one-third of early-stage HCC (hwang2024hepatocellularcarcinomaupdates pages 6-7).
MASLD-specific considerations (EASL-EASD-EASO 2024): surveillance is strongly recommended for MASLD-related cirrhosis; not recommended for non-cirrhotic MASLD/MASH without severe fibrosis (<F3), while F3 may be considered case-by-case; MRI can be used when ultrasound visualization is poor ((easo)2024easleasdeasoclinicalpractice pages 46-48, (easo)2024easleasdeasoclinicalpractice pages 20-21).
International imaging guidelines converge that noninvasive HCC diagnosis applies only to high-risk patients, and relies on multiphasic contrast-enhanced CT or MRI as first-line diagnostic exams (cannella2024esressentialsdiagnosis pages 1-3, cannella2024esressentialsdiagnosis pages 3-5). Major imaging features include: - Non-rim arterial phase hyperenhancement (APHE) - Non-peripheral washout - Enhancing capsule - Threshold growth (e.g., LI-RADS ≥50% increase in <6 months) (cannella2024esressentialsdiagnosis pages 5-7, cannella2024esressentialsdiagnosis pages 7-10)
A guideline-comparison table (cropped) is available here and summarizes the major features and size thresholds across EASL/AASLD(LI-RADS)/APASL/KLCA-NCC frameworks (cannella2024esressentialsdiagnosis media b948aa3a).
Performance characteristics cited in ESR/ESGAR 2024: a cited meta-analysis reports similar specificity for CT and MRI (>90%) but higher sensitivity for MRI (61–82% vs 48–66%), supporting MRI preference for small lesions when feasible (cannella2024esressentialsdiagnosis pages 3-5).
Biopsy is generally reserved for inconclusive imaging or non-cirrhotic contexts; it carries risks (bleeding, seeding) and non-trivial false-negative rate (~33% reported in a guideline review) (seth2024clinicalpracticeguidelines pages 2-3).
Contemporary guideline syntheses describe the standard curative-intent options for early-stage disease: surgical resection, percutaneous ablation (e.g., RFA), and liver transplantation, with transplant selection often using Milan criteria (single ≤5 cm or ≤3 lesions each ≤3 cm, no macrovascular invasion or extrahepatic spread) (wu2024hepatocellularcarcinomasurveillance pages 1-2, seth2024clinicalpracticeguidelines pages 10-11).
Intermediate-stage disease often uses transarterial therapies (TACE) and other locoregional approaches; recent paradigms include combining locoregional with systemic therapy and conversion/downstaging approaches to enable later resection/transplant (li2024introductionto2023 pages 7-7, kinsey2024managementofhepatocellular pages 1-2).
Example real-world combination implementation (2024): TACE combined with atezolizumab+bevacizumab in an unresectable HCC multicenter cohort (n=92) had ORR 54.3% (mRECIST) / 41.3% (RECIST 1.1), median OS 15.9 months, median PFS 9.1 months, and grade 3/4 treatment-related AEs 16.3% (shen2024efficacyofatezolizumab pages 1-2).
ASCO Guideline Update (May 2024): - Preferred first-line (Child-Pugh A; ECOG PS 0–1): atezolizumab + bevacizumab or durvalumab + tremelimumab (gordan2024systemictherapyfor pages 1-2, gordan2024systemictherapyfor pages 2-4). - If contraindications to those combinations: sorafenib, lenvatinib, or durvalumab may be offered first-line (gordan2024systemictherapyfor pages 2-4). - Subsequent-line therapy depends on prior regimen; after atezo+bev, options include TKIs and ramucirumab for AFP ≥400 ng/mL; after durva+treme, a TKI is recommended; after sorafenib/lenvatinib, options include cabozantinib/regorafenib/ramucirumab (AFP ≥400) and immune checkpoint combinations (nivo+ipi) in selected patients (gordan2024systemictherapyfor pages 2-4, gordan2024systemictherapyfor pages 13-14). - Panel emphasizes variceal screening/management prior to atezo+bev because bevacizumab increases bleeding risk, and recommends caution for Child-Pugh B patients (gordan2024systemictherapyfor pages 4-5, gordan2024systemictherapyfor pages 14-14).
Pivotal efficacy benchmarks for atezolizumab+bevacizumab (IMbrave150): Updated median OS 19.2 vs 13.4 months compared with sorafenib (HR 0.66, 95% CI 0.52–0.85) (finn2024efficacyandsafety pages 2-4). A 2024 IMbrave150 subgroup analysis for Vp4 portal vein tumor thrombosis reported median OS 7.6 vs 5.5 months and median PFS 5.4 vs 2.8 months for atezo+bev vs sorafenib, with grade ≥3 treatment-related AEs 43% vs 48% (finn2024efficacyandsafety pages 1-2).
Real-world effectiveness (meta-analytic): A 2023 single-arm meta-analysis of atezo+bev (23 studies; 3168 patients) reported pooled median OS 14.7 months, median PFS 6.66 months, ORR 26% (RECIST, long-term), and grade ≥3 AEs 30% (gao2023efficacyandsafety pages 1-2).
Semi-annual ultrasound ± AFP surveillance in high-risk groups is the central population-level approach (wu2024hepatocellularcarcinomasurveillance pages 4-5, hwang2024hepatocellularcarcinomaupdates pages 6-7). For MASLD, surveillance is recommended for cirrhosis and individualized for F3 fibrosis ((easo)2024easleasdeasoclinicalpractice pages 46-48, (easo)2024easleasdeasoclinicalpractice pages 20-21).
No veterinary or wildlife comparative HCC evidence was retrieved in the current evidence set. (No claim can be supported here without additional targeted retrieval.)
A 2024 review summarizes HCC models spanning chemically/dietary induced models (e.g., DEN; CCl4; NASH diets), genetic/oncogene-driven models (including hydrodynamic tail vein injection and transposon systems), transplantation models (xenografts/PDX; heterotopic and orthotopic), and advanced ex vivo/in vitro platforms (precision-cut tissue slices, organoids, organ-on-chip) (cigliano2024preclinicalmodelsof pages 1-2, cigliano2024preclinicalmodelsof pages 17-18).
1) Systemic therapy sequencing remains complex: ASCO (2024) emphasizes shared decision-making (toxicity, cost, bleeding risk, autoimmune risk) and cautions extrapolation beyond trial populations (mostly Child-Pugh A), reflecting real-world complexity in patients with cirrhosis (gordan2024systemictherapyfor pages 2-4, gordan2024systemictherapyfor pages 14-14).
2) Noninvasive imaging diagnosis requires context: ESR/ESGAR (2024) stresses that noninvasive diagnosis is restricted to high-risk patients and requires combining major imaging features, not relying on a single sign; guideline differences around hepatobiliary phase features can alter sensitivity/specificity (cannella2024esressentialsdiagnosis pages 1-3, cannella2024esressentialsdiagnosis pages 7-10).
3) Etiology shift is altering detection and outcomes: The CMH 2024 epidemiology update argues ultrasound surveillance may perform worse as MASLD/ALD increase, and MASLD-associated HCC can arise without cirrhosis—challenging traditional “cirrhosis-only” surveillance paradigms (hwang2024hepatocellularcarcinomaupdates pages 6-7, hwang2024hepatocellularcarcinomaupdates pages 1-3).
References
(OpenTargets Search: hepatocellular carcinoma): Open Targets Query (hepatocellular carcinoma, 13 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(hwang2024hepatocellularcarcinomaupdates pages 1-3): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(kinsey2024managementofhepatocellular pages 1-2): Emily Kinsey and Hannah M. Lee. Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape. Cancers, 16:666, Feb 2024. URL: https://doi.org/10.3390/cancers16030666, doi:10.3390/cancers16030666. This article has 136 citations.
(cannella2024esressentialsdiagnosis pages 1-3): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(mattos2024hepatocellularcarcinomatherole pages 1-2): Angelo Zambam de Mattos, Isadora Zanotelli Bombassaro, Arndt Vogel, and Jose D Debes. Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice. World Journal of Gastroenterology, 30:2488-2495, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2488, doi:10.3748/wjg.v30.i19.2488. This article has 13 citations.
(hwang2024hepatocellularcarcinomaupdates pages 6-7): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(gordan2024systemictherapyfor pages 1-2): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
((easo)2024easleasdeasoclinicalpractice pages 46-48): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(shen2024efficacyofatezolizumab pages 1-2): Xiao Shen, Jin-Xing Zhang, Jin Liu, Sheng Liu, Hai-Bin Shi, Yuan Cheng, Qing-Qiao Zhang, Guo-Wen Yin, and Qing-Quan Zu. Efficacy of atezolizumab plus bevacizumab combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. Journal of Hepatocellular Carcinoma, 11:1993-2003, Oct 2024. URL: https://doi.org/10.2147/jhc.s478604, doi:10.2147/jhc.s478604. This article has 4 citations and is from a peer-reviewed journal.
(song2024genomicprofilinginforms pages 1-2): Mengqi Song, Haoyue Cheng, Hao Zou, Kai Ma, Lianfang Lu, Qian Wei, Zejiang Xu, Zirui Tang, Yuanzheng Zhang, Yinan Wang, and Chuandong Sun. Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice. BMC Cancer, Jun 2024. URL: https://doi.org/10.1186/s12885-024-12407-2, doi:10.1186/s12885-024-12407-2. This article has 8 citations and is from a peer-reviewed journal.
(hwang2024hepatocellularcarcinomaupdates pages 4-6): Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, and Ju Dong Yang. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, Dec 2024. URL: https://doi.org/10.3350/cmh.2024.0824, doi:10.3350/cmh.2024.0824. This article has 238 citations.
(peruhova2024geneticscreeningof pages 2-4): Milena Peruhova, Sonya Banova-Chakarova, Dimitrina Georgieva Miteva, and Tsvetelina Velikova. Genetic screening of liver cancer: state of the art. World Journal of Hepatology, 16:716-730, May 2024. URL: https://doi.org/10.4254/wjh.v16.i5.716, doi:10.4254/wjh.v16.i5.716. This article has 7 citations.
(ucdal2024crosstalkbetween pages 1-2): Mete Ucdal, Ayşe Buruş, and B. Çeltikçi. Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma. Hepatology Forum, 5:150-160, Jul 2024. URL: https://doi.org/10.14744/hf.2023.2023.0028, doi:10.14744/hf.2023.2023.0028. This article has 2 citations.
(wu2024hepatocellularcarcinomasurveillance pages 1-2): Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, and Mina S. Makary. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers, 16:3933, Nov 2024. URL: https://doi.org/10.3390/cancers16233933, doi:10.3390/cancers16233933. This article has 24 citations.
(seth2024clinicalpracticeguidelines pages 2-3): Ishith Seth, Adrian Siu, Lyndel Hewitt, Ulvi Budak, Beshoy Farah, and Mouhannad Jaber. Clinical practice guidelines for the management of hepatocellular carcinoma: a systematic review. Journal of Gastrointestinal Cancer, 55:318-331, Jul 2024. URL: https://doi.org/10.1007/s12029-023-00961-0, doi:10.1007/s12029-023-00961-0. This article has 4 citations.
(szilveszter2024molecularmechanismsin pages 2-4): Raluca-Margit Szilveszter, M. Muntean, and Adrian-Florin Florea. Molecular mechanisms in tumorigenesis of hepatocellular carcinoma and in target treatments—an overview. Biomolecules, 14:656, Jun 2024. URL: https://doi.org/10.3390/biom14060656, doi:10.3390/biom14060656. This article has 18 citations.
(pessino2024hepatocellularcarcinomaold pages 15-17): Greta Pessino, Claudia Scotti, and Maristella Maggi. Hepatocellular carcinoma: old and emerging therapeutic targets. Cancers, 16:901, Feb 2024. URL: https://doi.org/10.3390/cancers16050901, doi:10.3390/cancers16050901. This article has 42 citations.
(wang2024novelgeneticalterations pages 1-2): Yizhou Wang, Pei-pei Shang, Chang Xu, Wei Dong, Xiaofeng Zhang, Yong Xia, Chengjun Sui, and Cheng Yang. Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses. Frontiers in Pharmacology, Jun 2024. URL: https://doi.org/10.3389/fphar.2024.1416295, doi:10.3389/fphar.2024.1416295. This article has 3 citations.
((easo)2024easleasdeasoclinicalpractice pages 10-11): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(cigliano2024preclinicalmodelsof pages 9-10): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(kassem2024genomiclandscapeof pages 1-2): Perihan Hamdy Kassem, Iman Fawzy Montasser, Ramy Mohamed Mahmoud, Rasha Ahmed Ghorab, Dina A. AbdelHakam, Marium EL Sayed Ahmad Fathi, Marwa A. Abdel Wahed, Khaled Mohey, Mariam Ibrahim, Mohamed El Hadidi, Yasmine M. Masssoud, Manar Salah, Arwa Abugable, Mohamad Bahaa, Sherif El Khamisy, and Mahmoud El Meteini. Genomic landscape of hepatocellular carcinoma in egyptian patients by whole exome sequencing. BMC Medical Genomics, Aug 2024. URL: https://doi.org/10.1186/s12920-024-01965-w, doi:10.1186/s12920-024-01965-w. This article has 5 citations and is from a peer-reviewed journal.
(li2024singlecellanalyses pages 1-2): Yao Li, Fengwei Li, Lei Xu, Xiaodong Shi, Hui Xue, Jianwei Liu, Shilei Bai, Yeye Wu, Zhao Yang, Feng Xue, Yong Xia, Hui Dong, Feng Shen, and Kui Wang. Single cell analyses reveal the pd-1 blockade response-related immune features in hepatocellular carcinoma. Theranostics, 14:3526-3547, Jun 2024. URL: https://doi.org/10.7150/thno.95971, doi:10.7150/thno.95971. This article has 22 citations and is from a domain leading peer-reviewed journal.
(li2024singlecellanalyses pages 6-8): Yao Li, Fengwei Li, Lei Xu, Xiaodong Shi, Hui Xue, Jianwei Liu, Shilei Bai, Yeye Wu, Zhao Yang, Feng Xue, Yong Xia, Hui Dong, Feng Shen, and Kui Wang. Single cell analyses reveal the pd-1 blockade response-related immune features in hepatocellular carcinoma. Theranostics, 14:3526-3547, Jun 2024. URL: https://doi.org/10.7150/thno.95971, doi:10.7150/thno.95971. This article has 22 citations and is from a domain leading peer-reviewed journal.
(guo2024singlecelltumorheterogeneity pages 1-2): De-Zhen Guo, Xin Zhang, Sen-Quan Zhang, Shi-Yu Zhang, Xiang-Yu Zhang, Jia-Yan Yan, San-Yuan Dong, Kai Zhu, Xin-Rong Yang, Jia Fan, Jian Zhou, and Ao Huang. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts. Molecular Cancer, Aug 2024. URL: https://doi.org/10.1186/s12943-024-02062-3, doi:10.1186/s12943-024-02062-3. This article has 69 citations and is from a highest quality peer-reviewed journal.
(seth2024clinicalpracticeguidelines pages 10-11): Ishith Seth, Adrian Siu, Lyndel Hewitt, Ulvi Budak, Beshoy Farah, and Mouhannad Jaber. Clinical practice guidelines for the management of hepatocellular carcinoma: a systematic review. Journal of Gastrointestinal Cancer, 55:318-331, Jul 2024. URL: https://doi.org/10.1007/s12029-023-00961-0, doi:10.1007/s12029-023-00961-0. This article has 4 citations.
(wu2024hepatocellularcarcinomasurveillance pages 4-5): Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, and Mina S. Makary. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers, 16:3933, Nov 2024. URL: https://doi.org/10.3390/cancers16233933, doi:10.3390/cancers16233933. This article has 24 citations.
((easo)2024easleasdeasoclinicalpractice pages 20-21): European Association for the Study of the Liver (EASL). Easl-easd-easo clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (masld). Obesity Facts, 17:374-444, Jun 2024. URL: https://doi.org/10.1159/000539371, doi:10.1159/000539371. This article has 316 citations and is from a peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 3-5): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 5-7): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis pages 7-10): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(cannella2024esressentialsdiagnosis media b948aa3a): Roberto Cannella, Marc Zins, and Giuseppe Brancatelli. Esr essentials: diagnosis of hepatocellular carcinoma—practice recommendations by esgar. European Radiology, 34:2127-2139, Feb 2024. URL: https://doi.org/10.1007/s00330-024-10606-w, doi:10.1007/s00330-024-10606-w. This article has 32 citations and is from a domain leading peer-reviewed journal.
(xie2023areviewof pages 1-2): Di-Yang Xie, Kai Zhu, Zheng-Gang Ren, Jian Zhou, Jia Fan, and Qiang Gao. A review of 2022 chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 12:216-228, Apr 2023. URL: https://doi.org/10.21037/hbsn-22-469, doi:10.21037/hbsn-22-469. This article has 157 citations and is from a peer-reviewed journal.
(li2024introductionto2023 pages 7-7): Jiexun Li, Zhuoran Qi, Jian Zhang, Sinuo Chen, and Jinglin Xia. Introduction to 2023 chinese expert consensus on the whole-course management of hepatocellular carcinoma. Hepatoma Research, Mar 2024. URL: https://doi.org/10.20517/2394-5079.2024.16, doi:10.20517/2394-5079.2024.16. This article has 0 citations.
(gordan2024systemictherapyfor pages 2-4): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 13-14): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 4-5): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(gordan2024systemictherapyfor pages 14-14): John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Eliza Beal, Richard S. Finn, Terence P. Gade, Laura Goff, Shilpi Gupta, Jennifer Guy, Hang T. Hoang, Renuka Iyer, Ishmael Jaiyesimi, Minaxi Jhawer, Asha Karippot, Ahmed O. Kaseb, R. Kate Kelley, Jeremy Kortmansky, Andrea Leaf, William M. Remak, Davendra P.S. Sohal, Tamar H. Taddei, Andrea Wilson Woods, Mark Yarchoan, and Michal G. Rose. Systemic therapy for advanced hepatocellular carcinoma: asco guideline update. Journal of Clinical Oncology, 42:1830-1850, May 2024. URL: https://doi.org/10.1200/jco.23.02745, doi:10.1200/jco.23.02745. This article has 285 citations and is from a highest quality peer-reviewed journal.
(finn2024efficacyandsafety pages 2-4): Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, and Valeriy Breder. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in imbrave150. Liver Cancer, 13:1-14, Jun 2024. URL: https://doi.org/10.1159/000539897, doi:10.1159/000539897. This article has 50 citations and is from a peer-reviewed journal.
(finn2024efficacyandsafety pages 1-2): Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, and Valeriy Breder. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in imbrave150. Liver Cancer, 13:1-14, Jun 2024. URL: https://doi.org/10.1159/000539897, doi:10.1159/000539897. This article has 50 citations and is from a peer-reviewed journal.
(gao2023efficacyandsafety pages 1-2): Xiaoqiang Gao, Rui Zhao, Huaxing Ma, and Shi Zuo. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. BMC Cancer, Jul 2023. URL: https://doi.org/10.1186/s12885-023-11112-w, doi:10.1186/s12885-023-11112-w. This article has 28 citations and is from a peer-reviewed journal.
(cigliano2024preclinicalmodelsof pages 1-2): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 17-18): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 7-9): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 15-17): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 20-21): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.
(cigliano2024preclinicalmodelsof pages 6-7): Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen, and Diego F. Calvisi. Preclinical models of hepatocellular carcinoma: current utility, limitations, and challenges. Biomedicines, 12:1624, Jul 2024. URL: https://doi.org/10.3390/biomedicines12071624, doi:10.3390/biomedicines12071624. This article has 26 citations.